Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth? | Annals of the Rheumatic Diseases

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article info

Clinical and epidemiological research

Extended report

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

Authors

Polina Putrik Department of Health Promotion and Education, Maastricht University, School for Public Health and Primary Care (CAPHRI), Maastricht, The Netherlands PubMed articles Google scholar articles
Sofia Ramiro Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Department of Rheumatology, Hospital Garcia de Orta, Almada, Portugal PubMed articles Google scholar articles
Tore K Kvien Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway PubMed articles Google scholar articles
Tuulikki Sokka Department of Medicine, Jyväskylä Central Hospital, Jyvaskyla, Finland PubMed articles Google scholar articles
Till Uhlig Department of Rheumatology, National Research Center for Rehabilitation in Rheumatology, Diakonhjemmet Hospital, Oslo, Norway PubMed articles Google scholar articles
Annelies Boonen Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center and School for Public Health & Primary Care (CAPHRI), University Maastricht, Maastricht, The Netherlands PubMed articles Google scholar articles
on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group
Google scholar articles

Correspondence to Polina Putrik, Department of Health Promotion and Education, Maastricht University, School for Public Health and Primary Care (CAPHRI), Peter Debyeplein 1, Maastricht 6229HA, The Netherlands; polina.putrik{at}gmail.com

Citation

Putrik P, Ramiro S, Kvien TK on behalf of Equity in Clinical Eligibility Criteria for RA treatment Working Group, et al

Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?

Annals of the Rheumatic Diseases 2014;73:2010-2021.

Publication history

Received April 21, 2013
Revised June 10, 2013
Accepted July 14, 2013
First published August 12, 2013.

Online issue publication

October 05, 2014

Article Versions

Previous version (12 August 2013).
Previous version (20 December 2013).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions